코로나바이러스감염증-19 치료제 현황
A Review of Current Drugs for COVID-19
2
조회
0
다운로드
0
인용
0
참고문헌
초록
In December 2019, a new coronavirus-related pneumonia occurred in Wuhan, Hubei province, Chi- na. The virus was named acute acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the World Health Organization named the disease COVID-19. The disease became pandemic, causing numerous patients and deaths in a short time. However, despite this epidemic situation, there are currently no Food and Drug Administration-approved drugs to treat with COVID-19. Therefore, in this review, we will discuss the drugs currently used in the treatment of COVID-19 based on the COVID-19 treatment guidelines issued by the Centers for Disease Control and Prevention.
Abstract
In December 2019, a new coronavirus-related pneumonia occurred in Wuhan, Hubei province, Chi- na. The virus was named acute acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the World Health Organization named the disease COVID-19. The disease became pandemic, causing numerous patients and deaths in a short time. However, despite this epidemic situation, there are currently no Food and Drug Administration-approved drugs to treat with COVID-19. Therefore, in this review, we will discuss the drugs currently used in the treatment of COVID-19 based on the COVID-19 treatment guidelines issued by the Centers for Disease Control and Prevention.
참고문헌 (24)
- "who.int"[URL]
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARSCoV-2", Nat Microbiol, 5, pp.536~544 (2020)
- "who.int"[URL]
- "who.int"[URL]
- 박수은, "Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)", Clinical and Experimental Pediatrics, 63(4), pp.119~124 (2020), 대한소아청소년과학회
- Heo JY, "Clinical and epidemiological characteristics of coronavirus disease 2019 in the early stage of outbreak", Korean J Med, 95, pp.67~73 (2020)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- Ren LL, "Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study", Chin Med J(Engl), 133, pp.1015~1024 (2020)
- "ncov.mohw.go.kr"[URL]
- "ncov.mohw.go.kr"[URL]
- 이무식, "지역사회와 함께 하는 코로나19(COVID-19) 극복", 농촌의학.지역보건, 45(1), pp.41~46 (2020), 한국농촌의학.지역보건학회
- "covid19treatmentguidelines.nih.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "Clinicaltrials.gov"[URL]
- "fda.gov"[URL]
- Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
- Williamson BN, "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2", ~
- 안대균, "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)", Journal of Microbiology and Biotechnology, 30(3), pp.313~324 (2020), 한국미생물·생명공학회
- Liu X, "Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines", J Genet Genomics, 47, pp.119~121 (2020)
- "jnj.com"[URL]